- Home
- ALT
ALT
Altimmune Inc.
as 05-30-2025 3:30pm EST
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 472.3M | IPO Year: | N/A |
| Target Price: | $21.00 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.55 - $11.16 | Next Earning Date: | 05-13-2025 |
| Revenue: | $20,000 | Revenue Growth: | -95.12% |
| Revenue Growth (this year): | 4108.32% | Revenue Growth (next year): | 3900.06% |
Stock Insider Trading Activity of Altimmune Inc. (ALT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sohn Catherine A. | ALT | Director | Mar 17 '25 | Buy | $5.78 | 1,000 | $5,784.50 | 1,000 | |
| WEAVER GREGORY L | ALT | Chief Financial Officer | Mar 13 '25 | Buy | $5.20 | 10,000 | $51,996.00 | 10,000 |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
TipRanks
17 days ago
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
GlobeNewswire
17 days ago
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire
18 days ago
Altimmune Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
18 days ago
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GlobeNewswire
23 days ago
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
GlobeNewswire
25 days ago
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GlobeNewswire
a month ago
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.